Vimarsana
Biggest News Aggregation in the World

Page 3 - Daniel Spratt News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Daniel Spratt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Daniel Spratt Today - Breaking & Trending Today

Ongoing Research Aims to Enhance Radiotherapy Techniques in Prostate Cancer - Vimarsana News

Ongoing Research Aims to Enhance Radiotherapy Techniques in Prostate Cancer

Daniel Spratt, MD, discusses the expanded role of radiation therapy for the treatment of patients with prostate cancer, delves into the optimal approach for using radiation in tandem with hormonal therapy for these patients, and highlights ongoing research focused on minimizing adverse effects associated with radiotherapy.

Sotorasib's Confirmatory Data in NSCLC Unreliable, Says FDA Panel - Vimarsana News

Sotorasib's Confirmatory Data in NSCLC Unreliable, Says FDA Panel

But agency doesn't plan to immediately push for KRAS inhibitor's withdrawal

New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte's Decipher Prostate Genomic Classifier - Vimarsana News

New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte's Decipher Prostate Genomic Classifier

Findings presented at the 2023 ASTRO Annual Meeting expand substantial body of evidence demonstrating Decipher Prostate test’s ability to help inform prostate cancer treatment...

AI-Based Predictive Model Could Spare Use of Prostate Cancer ADT - Vimarsana News

AI-Based Predictive Model Could Spare Use of Prostate Cancer ADT

A predictive model based on artificial intelligence may guide the use of androgen deprivation therapy for men with intermediate-risk prostate cancer.

AI-Based Predictive Model Could Spare Use of Prostate Cancer ADT - Vimarsana News

AI-Based Predictive Model Could Spare Use of Prostate Cancer ADT

A predictive model based on artificial intelligence may guide the use of androgen deprivation therapy for men with intermediate-risk prostate cancer.